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Abstract
Fibroepithelial lesions with cellular stroma are frequently termed cellular fibroadenomas although 
criteria for distinguishing them from a phyllodes tumor are vague and subjective. However, the 
clinical implications and surgical management for these 2 lesions may be different. We randomly 
selected 21 cases of fibroepithelial lesions sent in consultation to the senior author that were 
challenging to classify as cellular fibroadenoma or phyllodes tumor. One to 2 representative slides 
of each case along with patient age were sent to 10 pathologists who specialize in breast 
pathology. The World Health Organization criteria for phyllodes tumors and a diagnosis form 
were included with the study set. For the purposes of data reporting, fibroadenoma and cellular 
fibroadenoma are considered together. In only 2 cases was there uniform agreement as to whether 
the tumor represented a fibroadenoma or phyllodes tumor. Of the remaining 19 cases, if the 
diagnoses of fibroadenoma and benign phyllodes tumor were combined and separated from 
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borderline and malignant phyllodes tumors, there was 100% agreement in 53% of cases and 90% 
agreement in 79% of cases. This study highlights the difficulty that exists in distinguishing some 
cellular fibroadenomas from phyllodes tumors even for pathologists who specialize in breast 
pathology. However, there appears to be considerable agreement when cellular fibroadenomas and 
benign phyllodes tumors are distinguished from borderline and malignant phyllodes tumors. 
Further studies are needed to determine if there is a clinically significant difference between 
cellular fibroadenomas and benign phyllodes tumors and how to better distinguish them from 
borderline and malignant phyllodes tumors.
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Introduction
Fibroepithelial lesions of the breast with cellular stroma are frequently called cellular 
fibroadenomas and occasional cases can be difficult to distinguish from phyllodes tumors. 
While criteria have been established for diagnosing phyllodes tumors,1 many of these 
lesions have overlapping features and there is no single criterion to distinguish a 
fibroadenoma from a cellular fibroadenoma or a cellular fibroadenoma from a benign 
phyllodes tumor. This is not a trivial distinction as the clinical implications and surgical 
management for these lesions may be different at some centers. In this study, we attempted 
to determine the degree of inter-observer variability between pathologists in classifying a 
group of fibroepithelial lesions exhibiting varying degrees of stromal cellularity, atypia, 
mitotic activity, and intracanalicular growth.
Materials and Methods
The senior author (CR) searched the consultation files at Mayo Clinic spanning a 25-year 
period (1986-2010) for cases that were submitted for second opinion because of difficulty in 
classifying the lesion in question as a fibroadenoma or a phyllodes tumor. From this search, 
21 of the identified cases were randomly selected for this study. One to 2 representative 
slides of each case along with patient age were sent to 10 pathologists who specialize in 
breast pathology. The 2003 World Health Organization (WHO) criteria for phyllodes tumor2 
were included with the study set as well as a diagnosis form that included an “other” 
category (Table 1). All pathologists reviewed the same slides; no recuts were performed. 
Following review, each pathologist mailed the study set to the next pathologist on the list 
and diagnoses forms were returned independently to the first author only. For the purposes 
of data reporting, fibroadenoma and cellular fibroadenoma are considered together.
Results
The pathologists’ diagnoses for each of the 21 study cases are listed in Table 1. In only 2 
cases was there uniform agreement as to whether the tumor represented a fibroadenoma 
(case 16, Figure 1) or phyllodes tumor (case 4, Figure 2). However, in the phyllodes tumor 
case, subclassification varied from benign to malignant. Of the remaining 19 cases, in 4 
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cases the diagnoses were split nearly equally (5/5 or 6/4) between cellular fibroadenoma and 
benign phyllodes tumor (cases 1 and 10, Figures 3 and 4, respectively). Of note, in case 10 
in which 6 pathologists diagnosed benign phyllodes tumor, of the 4 other pathologists, 2 
diagnosed cellular fibroadenoma and 2 simply fibroadenoma. In 9 cases, the diagnoses 
ranged from fibroadenoma to borderline phyllodes tumor. In 4 of these cases, more than 1 
pathologist made the diagnosis of borderline phyllodes tumor (cases 2 and 9, Figures 5 and 
6, respectively). If the diagnoses of fibroadenoma/cellular fibroadenoma and benign 
phyllodes tumor were combined and separated from the borderline and malignant phyllodes 
tumors, there was 100% agreement in 53% of cases (10/19) and 90% agreement in 79% of 
cases (15/19).
Discussion
The diagnostic distinction of fibroadenomas with cellular stroma (cellular fibroadenomas) 
and phyllodes tumors is based on the “best fit” within a set of 6 criteria established by the 
WHO.1 In most cases the diagnosis is straightforward. However, occasional cases with 
significantly overlapping features remain a challenge to classify as there is no single 
histologic feature unequivocally separating the two.3-5 This distinction usually involves 
deciding between a cellular fibroadenoma and a benign phyllodes tumor, but in our study 
nine of the 21 cases (43%) had diagnoses ranging from fibroadenoma to borderline 
phyllodes tumor. Thus, even pathologists who specialize in breast pathology disagreed 
significantly not only in separating fibrodenomas from benign phyllodes tumors but also in 
distinguishing the subclasses of phyllodes tumors in these challenging cases. Unfortunately, 
these distinctions are not without consequence, as the decision for further surgical treatment, 
particularly for the borderline and malignant phyllodes tumors, sometimes rests on these 
subjective criteria. In attempts to improve on pathologists’ ability to better distinguish types 
of fibroepithelial lesions, numerous studies have looked at using immunohistochemical 
markers, but to date none has proven to be useful in everyday practice and histology remains 
the current standard.6
If the criteria used to distinguish different types of fibroepithelial lesions remain subjective, 
and pathologists cannot agree on the various subclassifications, why do we continue to make 
these distinctions? The predominant reason is to determine the likelihood of a particular 
fibroepithelial lesion recurring and/or possibly metastasizing. Within phyllodes tumors, 
recurrence rates tend to increase from benign to borderline to malignant.4,5,7-9 For benign 
phyllodes tumors, recurrence rates are generally reported to be 20% or less.4,5 Recurrence 
rates as high as 17% have also been reported in fibroadenomas.5,10 Additionally, unlike for 
borderline or malignant phyllodes tumors, studies have suggested that additional surgery 
following a diagnosis of benign phyllodes tumor may not be necessary as recurrence rates 
were not significantly affected by margin status.8,11,12 This begs the following question: If 
the likelihood of recurrence is similar between a cellular fibroadenoma and a benign 
phyllodes tumor and additional surgery for clear margins may not be beneficial for either, 
why separate these 2 diagnoses? One possible reason is that there are studies that have 
identified benign phyllodes tumors recurring as borderline or malignant tumors and there are 
rare reports of benign phyllodes tumors metasta-sizing.9,13-20 However, a large review of the 
literature7 showed that the overall rate of histologic progression from a benign phyllodes 
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tumor to a higher grade on average is very low (4%) and some of these studies commented 
that possibly due to inadequate tissue sampling, more “malignant” areas of the original 
tumor might not have been identified.14,16,17
Given the current literature, it seems there is minimal if any significant difference in clinical 
behavior between a cellular fibroadenoma and a benign phyllodes tumor in terms of 
likelihood of recurrence or progression to a higher-grade tumor. In our study, we found 
considerable agreement when cellular fibroadenomas and benign phyllodes tumors are 
distinguished from borderline and malignant phyllodes tumors. We agree with the proposal 
in the 2012 WHO Classification of Tumours of the Breast1 suggesting that, in difficult 
cases, a diagnosis of fibroepithelial lesion be rendered so as to avoid unnecessary additional 
surgical treatment and to convey that these lesions are currently not reproducibly 
distinguished by pathologists. Further studies are needed to focus on the establishment of 
criteria to better distinguish benign phyllodes tumors from borderline and malignant tumors, 
since this distinction is the one that appears to have clinical significance.
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Case 16: All 10 pathologists diagnosed this lesion as either fibroadenoma or cellular 
fibroadenoma (hematoxylin and eosin; 4× and 40×).
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Case 4: All 10 pathologists diagnosed this lesion as a phyllodes tumor, with 7 diagnosing it 
as borderline, 2 as malignant, and 1 as benign (hematoxylin and eosin; 4× and 20×).
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Case 1: This lesion was diagnosed cellular fibroadenoma by 5 pathologists and benign 
phyllodes tumor by 5 pathologists (hematoxylin and eosin; 4× and 40X×).
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Case 10: This lesion was diagnosed benign phyllodes tumor by 6 pathologists and 
fibroadenoma or cellular fibroadenoma by 4 pathologists (hematoxylin and eosin; 4× and 
10×).
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Case 2: This lesion was diagnosed cellular fibroadenoma by 4 pathologists and borderline 
phyllodes tumor by 4 pathologists. The remaining diagnoses were benign phyllodes tumor 
and nodular pseudoangiomatous stromal hyperplasia (hematoxylin and eosin; 4× and 20×).
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Case 9: This lesion was diagnosed benign phyllodes tumor by 6 pathologists, borderline 
phyllodes tumor by 3 pathologists, and cellular fibroadenoma by 1 pathologist (hematoxylin 
and eosin; 2× and 10×).
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Table 1
Distribution of the 10 Study Pathologists' Diagnoses for Each of the 21 Study Cases.
Case No./Age (Years) Fibroadenoma, n Benign PT, n Borderline PT, n Malignant PT, n Other
1/21 5 5 0 0
2/22 4 1 4 0 Nodular PASH
3/44 7 3 0 0
4/65 0 1 7 2
5/13 6 3 1 0




a 1 0 0 Hamartoma
8/24 6 4 0 0
9/54 1 6 3 0
10/53 4 6 0 0
11/39 6 2 1 0 Sclerosing lobular hyperplasia
12/38 3 3 3 0 Periductal stromal sarcoma
13/32 6 4 0 0
14/53
8
a 2 0 0
15/26 1 8 1 0
16/36 10 0 0 0
17/18 8 2 0 0
18/32 6 2 2 0
19/14 9 0 1 0
20/16 7 3 0 0
21/20 6 3 1 0
Abbreviations: PT, phyllodes tumor; PASH, pseudoangiomatous stromal hyperplasia.
a
In cases 7 and 14 several pathologists modified the fibroadenoma diagnosis to complex fibroadenoma.
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